Topic
Financial Reporting
Showing 41 to 50 of 102 results using the term “Financial Reporting”
EARNINGS ANALYSIS: Waystar Expects Patient Visits to Increase; Clients Focused on Solutions to Address Claim Denials
Credit Research: Kyle Owusu, CFA Relevant Document: Q4 2024 Earnings Results Revenue cycle management company Waystar said during its fourth-quarter 2024 earnings call that it sees strong demand and expects patient visits to increase with more people using the healthcare system. The company’s...
Published on Feb 18, 2025
Q4 Earnings Weekly: Week Ended Jan. 31 – Financials Lead the Way, Median Top Line & EBITDA Growth Relatively Flat Across the Rest of the Universe; Net Leverage Exposure Reduced
Relevant Items: Q3 Earnings Analytics Fundamentals by Octus With fourth-quarter 2024 earnings reporting now underway, Octus, formerly Reorg, covered 79 companies spanning high-yield borrowers, leveraged loan issuers and other midmarket-leveraged credits outside of the major indices in the week...
Published on Feb 4, 2025
Octus on Credit: Tracking consumer spending the Octus way
Mark Fischer, Director of Credit Research, Americas Credit Certain consumer segments might be reaching their limits in terms of purchasing power resulting in hard choices being made between leisure services and goods. At least that’s what is suggested by Octus’ bottoms’ up...
Published on Jan 30, 2025
Tear Sheet: Lifestyle’s ‘25 Liquidity Likely Adequate; $350M Due’26 Repayment Contingent on Monetizing Financial Assets and Prime London Office, Refi/ Upsize SOGO CWB Facility, Positive FCF; Shareholder Likely Creditor-Friendly
Credit Research: Cathy Lu, Credit Analyst Credit Research: Junguang Tan, Senior Credit Analyst Relevant Documents: Excel File on Octus Analysis Page Lifestyle $350 million Senior Notes Due 2026 Offering Memorandum (OM) Lifestyle August 2022 Take-Private Disclosure Octus Asia Highlights: ‘25...
Published on Jan 9, 2025
Leveraged Finance Outlook: Market Participants Prep for Busy Primary Issuance in 2025 Boosted by Increased M&A, LBO Dealmaking
Reporting: Katherine Schwartz, Michael Haley Leveraged finance participants say they expect 2025 will usher in a long-anticipated boost in M&A and LBO activity that will bolster the debt capital markets. Although many investors and bankers were hopeful of an uptick in M&A activity in the...
Published on Dec 16, 2024
UPDATE 2: SP Group Targets Upsized, ~$3.2B NCDs To Refi Ares, Farallon; Security Likely To Include Energy, Real Estate Assets Along with Tata Sons Shares
Wed Dec 11, 2024 03:25 AM ET: Reporting: Malvika Joshi, Bhakti Tambe Shapoorji Pallonji Group, or SP group, has upsized its planned offering of private, Tata Sons-shares-backed, three-year INR-denominated non-convertible debentures, or NCDs, to around $3.2 billion-equivalent from $2.6 billion, four...
Published on Dec 11, 2024
BharatPe Places INR 1.25B Private NCDs With Neo Credit Alternatives Investment, Neo Wealth
Reporting: Malvika Joshi, Bhakti Tambe Indian fintech and digital payment company Resilient Innovations Private Ltd, popularly known as BharatPe, has privately placed non-convertible debentures, or NCDs, totalling INR 1.25 billion ($14.8 million) with Neo Credit Alternatives Investment Trust and...
Published on Dec 3, 2024
UPDATE 13: Vedanta Resources Plans USD Bond Issuance to Refi Outstanding 13.875% 2028 Bonds, 9.25% 2026 Notes in Q1 CY’25
Wed Dec 04, 2024 08:43 AM ET: Editor’s Note: The following story was published in the evening on Dec. 4 and has been reissued during regular business hours to reach a wider audience. Reporting: Malvika Joshi Vedanta Resources Ltd. or VRL, told investors today, Dec. 4, that it plans to issue...
Published on Dec 4, 2024
Barings Prices Europe’s First Ever Private Credit CLO
Reporting: Hugh Minch Barings has priced the first ever private credit CLO in the European market, the firm has announced. BNP Paribas arranged Barings Euro Middle Market CLO at €380.6 million. The CLO has a combined €235.6 million triple-A notes split across three tranches, each...
Published on Nov 21, 2024
Seqens Loans Slide as PAP Slump Causes Q3 EBITDA to Be 54% Below Budget; Group Guides to €110M FY’24 EBITDA
Reporting: Robert Schach; Farooq Baloch French pharmaceutical solution and specialty chemicals producer Seqens’ loans dropped around 8 to 9 points after third-quarter earnings missed budget by 54% as a result of a deepening slump in the group’s core para-aminophenol, or PAP, market. Seqens’...
Published on Nov 20, 2024